Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives
Pharmaceutics · 28.08.2024 · 16 (9) · 1135
DOI: 10.3390/pharmaceutics16091135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.08.2024. Verfasst von Shengcang Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beij…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing National Laboratory for Molecular Sciences.
Abstract (Originalsprache)
Radiodynamic therapy (RDT), as an emerging cancer treatment method, has attracted attention due to its remarkable therapeutic efficacy using low-dose, high-energy radiation (such as X-rays) and has shown significant potential in cancer treatment. The RDT system typically consists of scintillators and photosensitizers (PSs). Scintillators absorb X-rays and convert them to visible light, activating nearby PSs to generate cytotoxic reactive oxygen species (ROS). Challenges faced by the two-component strategy, including low loading capacity and inefficient energy transfer, hinder its final effectiveness. In addition, the tumor microenvironment (TME) with hypoxia and immunosuppression limits the efficacy of RDTs. Recent advances introduce one-component RDT systems based on nanomaterials with high-Z metal elements, which effectively inhibit deep-seated tumors. These novel RDT systems exhibit immune enhancement and immune memory, potentially eliminating both primary and metastatic tumors. This review comprehensively analyzes recent advances in the rational construction of RDTs, exploring their mechanisms and application in the treatment of deep-seated tumors. Aimed at providing a practical resource for oncology researchers and practitioners, the review offers new perspectives for potential future directions in RDT research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
- Research and Development Department, Allife Medicine Inc., Beijing 100176, China.
- Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
- State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.
ORCID-Profile: Rongcheng Han
Förderung
- National Natural Science Foundation of China
- Beijing National Laboratory for Molecular Sciences
Zitieren
APA
Zhu, S., Lin, S., & Han, R. (2024). Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives. Pharmaceutics, 16(9), 1135. https://doi.org/10.3390/pharmaceutics16091135
Vancouver
Zhu S, Lin S, Han R. Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives. Pharmaceutics. 2024;16(9):1135. doi:10.3390/pharmaceutics16091135
BibTeX
@article{Zhu2024,
author = {Zhu, Shengcang and Lin, Siyue and Han, Rongcheng},
title = {Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {9},
pages = {1135},
doi = {10.3390/pharmaceutics16091135}
}
EUVIMED